Piperidine/piperazine-type inhibitors of p38 kinase

Details Piperidine/piperazine-type inhibitors of p38 kinase Piperidine/piperazine-type inhibitors of p38 kinase

2001-11-20

2004-02-24

Shah, Mukund J. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S180000, C544S182000, C544S236000, C544S238000, C544S257000, C544S279000, C544S333000, C544S350000, C546S114000, C546S115000, C546S121000, C546S122000, C546S139000, C546S194000, C546S199000, C546S208000, C546S202000, C546S209000, C546S211000, C546S212000, C546S214000, C514S242000, C514S248000, C514S252030, C514S255050, C514S259300, C514S259200, C514S259410, C514S256000, C514S300000, C514S301000, C514S302000, C514S314000, C514S318000, C514S319000, C514S320000, C514S321000, C514S322000, C514S323000, C514S

Reexamination Certificate

active

06696443

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to treating various disorders associated with enhanced activity of kinase p38-&agr;. More specifically, it concerns piperadine and piperazine derivatives useful in these methods.
BACKGROUND ART
A large number of chronic and acute conditions have been recognized to be associated with perturbation of the inflammatory response. A large number of cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-1 and TNF. Therefore, inhibitors of the kinase activity of p38 are useful anti-inflammatory agents.
Eye diseases associated with a fibroproliferative condition include retinal reattachment surgery accompanying proliferative vitreoretinopathy, cataract extraction with intraocular lens implantation, and post glaucoma drainage surgery.
PCT applications WO98/06715, WO98/07425, and WO 96/40143, all of which are incorporated herein by reference, describe the relationship of p38 kinase inhibitors with various disease states. As mentioned in these applications, inhibitors of p38 kinase are useful in treating a variety of diseases associated with chronic inflammation. These applications list rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases such as osteoporosis, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
The above-referenced PCT applications disclose compounds which are p38 kinase inhibitors said to be useful in treating these disease states. These compounds are either imidazoles or are indoles substituted at the 3- or 4-position with a piperazine ring linked through a carboxamide linkage. Additional compounds which are conjugates of piperazines with indoles are described as insecticides in WO97/26252, also incorporated herein by reference.
Certain aroyl/phenyl-substituted piperazines and piperidines which inhibit p38-&agr; kinase are described in PCT publication WO00/12074 published Mar. 9, 2000. In addition, indolyl substituted piperidines and piperazines which inhibit this enzyme are described in PCT publication No. WO99/61426 published Dec. 2, 1999. Carbolene derivatives of piperidine and piperazine as p38-&agr; inhibitors are described in PCT/US00/07934 filed Mar. 24, 2000.
None of the foregoing patents describes the piperadine type derivatives described herein which specifically inhibit p38-&agr;.
SUMMARY OF THE INVENTION
The invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38-&agr; activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease as further described below.
Compounds of the invention inhibit p38 kinase, the &agr;-isoform in particular, and are thus useful in treating diseases mediated by these activities. The compounds of the invention are of the formula (1):
and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein:
Ar
1
is an aryl group substituted with 0-5 non-interfering substituents, wherein two adjacent noninterfering substituents can form a fused aromatic or nonaromatic ring;
L
1
and L
2
are linkers;
each R
1
is independently a noninterfering substituent;
Z
1
is CR
2
or N wherein R
2
is hydrogen or a noninterfering substituent;
mis 0-4;
each of n and p is an integer from 0-2 wherein the sum of n and p is 0-3;
Ar
2
is a substantially planar, monocyclic or polycyclic aromatic moiety having one or more optional ring heteroatoms, said moiety being optionally substituted with one or more non-interfering substituents, two or more of which may form a fused ring;
Z is —W
1
—COX
j
Y wherein Y is COR
3
or an isostere thereof; R
3
is a noninterfering substituent, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1;
wherein the smallest number of covalent bonds in the compound separating the atom of Ar
1
bonded to L
2
to the atom of Ar
2
bonded to L
1
is at least 6, where each of said bonds has a bond length of 1.2 to 2.0 angstroms; and/or wherein the distance in space between the atom of Ar
1
bonded to L
2
and the atom of Ar
2
bonded to L
1
is 4.5-24 angstroms;
with the proviso that the portion of the compound represented by Ar
2
—Z is not
 wherein
represents a single or double bond; n is 0-3; one Z
2
is CA or CRA and the other is CR, CR
2
, NR or N; A is —W
i
—COX
j
Y wherein Y is COR or an isostere thereof, each of W and X is a spacer of 2-6 Å, and each of i and j is independently 0 or 1; Z
3
is NR or O; and each R is independently hydrogen or a noninterfering substituent.
The invention is further directed to methods of treating inflammation or proliferative conditions using these compounds. The invention is also directed to treating conditions associated with cardiac failure and Alzheimer's disease using the invention compounds.
DETAILED DESCRIPTION
The compounds of formula (1) are useful in treating conditions which are characterized by overactivity of p38 kinase, in particular the &agr;-isoform. Conditions “characterized by enhanced p38-&agr; activity” include those where this enzyme is present in increased amount or wherein the enzyme has been modified to increase its inherent activity, or both. Thus, “enhanced activity” refers to any condition wherein the effectiveness of these proteins is undesirably high, regardless of the cause.
The compounds of the invention are useful in conditions where p38-&agr; kinase shows enhanced activity. These conditions are those in which fibrosis and organ sclerosis are caused by, or accompanied by, inflammation, oxidation injury, hypoxia, altered temperature or extracellular osmolarity, conditions causing cellular stress, apoptosis or necrosis. These conditions include ischemia-reperfusion injury, congestive heart failure, progressive pulmonary and bronchial fibrosis, hepatitis, arthritis, inflammatory bowel disease, glomerular sclerosis, interstitial renal fibrosis, chronic scarring diseases of the eyes, bladder and reproductive tract, bone marrow dysplasia, chronic infectious or autoimmune states, spinal chord injury and traumatic or surgical wounds. These conditions, of course, would be benefited by compounds which inhibit p38-&agr;. Methods of treatment with the compounds of the invention are further discussed below.
The compounds useful in the invention are derivatives of piperadine/piperazine-type compounds containing a mandatory substituent, Z attached to the aromatic moiety Ar
2
The aromatic moiety is a substantially planar, monocyclic or polycyclic aromatic moiety having one or more optional ring heteroatoms. The aromatic moiety may be optionally substituted with one or more non-interfering substituents, two or more of which may form a fused ring.
In somewhat greater detail the aromatic moiety Ar
2
comprises an optionally substituted monocyclic or polycyclic aromatic nucleus, wherein the aromatic nucleus consists of a carbocyclic or heterocyclic ring selected from (i) a five-membered heterocyclic or carbocyclic ring (ii) a six-membered carbocyclic or heterocyclic ring; (iii) a five-membered carbocyclic or heterocyclic ring fused to another five-membered carbocyclic or heterocyclic ring; (iv) a six-m

Affiliated with

Also associated with

Rating

Piperidine/piperazine-type inhibitors of p38 kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine/piperazine-type inhibitors of p38 kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine/piperazine-type inhibitors of p38 kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3305890